Novocure’s shares are significantly reduced this year, partly due to the constant net losses.
However, the company is making significant clinical and regulatory progress.
Although there are some risks, the stock can increase due to significant catalysts.
10 shares we like better than Novocure ›
It was a challenging year for Novocure(Nasdaq: NVCR)Biotechnologically focused on oncology. The action decreased by 35% since early January. Although market problems may not have helped, Novocure is mostly guilty of its annual results. His shares decreased after a disappointing update of the fourth quarter.
However, the stock can have considerable potential at the top. The average price price of Novocure on Wall Street is $ 32.57, according to Yahoo! Finance. This means that it can jump with almost 70% of its current levels. Should investors be as scourge as Novocure Street?
Image source: Getty Images.
Novocure develops and offers on the market wearable devices that release electric fields known as TTFIELDS treatment fields that inhibit cancer cell growth. These devices do not necessarily replace traditional therapies; They are often used at the same time as them (although in some cases they can be self -healing). This innovative approach to treating one of the leading causes of death worldwide has found some success.
Novocure Markets Two devices: Optune Gio, cleared for the treatment of aggressive brain cancer called glioblastoma, and Optune Lua, approved to target both metastatic non -cellar lung cancer (NSCLC) and malignant pipralic pleura The greater acceptance of these devices in the markets where they are available helps to improve Novocure’s financial results. In the first quarter, the company’s revenue increased by 12% compared to a year to $ 155 million.
He had 4 268 active patients at the end of the period, an increase of 11% compared to the period a year ago. However, Novocure remains unprofitable; His net loss of action in the first quarter was $ 0.31. It is true that this was better than the reported $ 0.36 over the year ago. But given the uncertain environment and current market instability, investors may have a thorough bias for well -established, profitable shares at the moment.
Thus, Novocure’s shares can remain a little violent in the short term. Recent developments, however, can help the company turn things around and match street estimates.
Novocure has achieved several clinical and regulatory stages in the last six months. In April, he was authorized from the relevant European Optune Lua body for the treatment of metastatic NSCLC. Novocure estimates that over 400,000 patients have been diagnosed with NSCLC every year on the continent. Although its device will only focus on a small part of this amount, the regulatory nods significantly expands its addressable market.
Optune Lua has been approved in the US for NSCLC only since October. In the United States, approximately 30,000 patients have become eligible for the 193,000 NSCLC diagnoses. Novocure still has a massive white space in this niche – even if you reach 5,000 patients alone in NSCLC, it would be a giant victory for the company.
In December, in December, he announced positive results from a clinical trial of Phase 3 for his ttfields as an insoluble, topically advanced adenocarcinoma of the pancreas. This was the first time every treatment has shown a statistically significant benefit of the overall survival for patients with this type of pancreatic cancer, which is most inaccessible to current care standards. He has a five -year survival rate of only 13%, while his mortality rate increases, even when they decrease in most other cancers. Novocure evaluates 67,000 annual diagnoses in the United States, so there is a huge unsatisfied need.
It seems that the company is likely to provide another key approval here and will continue to make progress in this area. Still, shares are still massively declining for the year, although it has jumped after recent developments, including NSCLC approval in Europe. What does it give? Novocue’s successive net losses remain a problem.
However, if you are ready to look at these and somewhat increased risk they add to the stock, Novocure can be an excellent pickup at current levels. In anticipation of approval in pancreatic cancer and solid progress in NSCLC revenue can increase significantly and allow the healthcare professional to make a profit.
Wall Street analysts may be here. But if you follow their lead, it is essential to start with a small position in the stock and then add more only once (or if) it continues to show good progress.
Before you buy a warehouse in Novocure, think about it:
Thehe Motley Fool stock adviser Analyst team has just identified what they think is 10 best shares For investors to buy now … and Novocure was not one of them. The 10 shares that made the abbreviation could lead to the return on monsters in the coming years.
Consider whenNetflixMake this list on December 17, 2004 … If you have invested $ 1,000 at the time of our recommendation,You will have $ 639 271! ** Or when NvidiaMake this list on April 15, 2005 … If you have invested $ 1,000 at the time of our recommendation,You will have $ 804,688! **
It is now worth notingStock adviserThe total average return is957%-prevailing destruction of superiority compared to167%for S&P 500. Don’t miss the top 10 list available when you joinStock adviserS
See the 10 shares »
*Stock Advisor since May 19, 2025
Proser Junior Bakiny has no position in any of the mentioned shares. Motley Fool has positions and recommends Novocure. Motley Fool has a policy of disclosure.
1 stock with 35% this year you will regret not bought DIP, according to Wall Street originally published by Motley Fool
